Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg
DOI: 10.1055/s-0045-1807761
Original Article

Comparison of Quality of Life in Postoperative High-Grade Glioma Patients Treated Using EORTC and RTOG Target Delineation Techniques for Postoperative Radiotherapy

Shreyosi Mandal 
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
2   Department of Radiation Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Deepa Joseph
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
,
Ajay Krishnan
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
3   Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, Uttar Pradesh, India
,
Pragya Singh
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
4   Royal Surrey Hospital NHS Foundation Trust, Guilford, United Kingdom
,
Rajnish Kumar Arora
5   Department of Neurosurgery, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
,
Udit Chauhan
6   Department of Radiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
,
Sweety Gupta 
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
,
Lekshmi R.
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
,
Manoj Gupta
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
› Author Affiliations
› Further Information
Also available at
  Permissions and Reprints

Abstract

Introduction High-grade gliomas (HGGs) have dismal prognosis even with multimodality treatment entailing surgery, radiotherapy, and chemotherapy. Hence, assessment of improvement in quality of life (QOL) for evaluating treatment is critical. Target delineation for radiotherapy in HGG is often done according to the European Organization for Research and Treatment of Cancer (EORTC) and Radiotherapy and Oncology Group (RTOG) contouring guidelines, which differs on exclusion and inclusion of peritumoral edema believed to harbor malignant cells; the guidelines have not been prospectively compared for probable difference in QOL, considering the probable difference in treated volume.

Objective This article compares QOL in HGG patients receiving postoperative radiotherapy using target volume delineation based on the RTOG or EORTC guidelines.

Materials and Methods In this single-center, prospective randomized exploratory study, postoperative HGG patients were randomized to either receive radiotherapy according to the EORTC guidelines of target delineation (60 Gy/30 fractions to tumor bed and residual tumor) or the RTOG guidelines (46 Gy/23fractions to tumor bed, residual tumor, and peritumoral edema with 14 Gy/7 fraction boost to the tumor bed and residual tumor) with concurrent temozolomide (TMZ) followed by 6 months of adjuvant TMZ. The aim and primary endpoint of the study was to assess and compare QOL between the arms. Descriptive statistics were used to convey demographic data, proportions for categorical variables, and mean, median, range, and standard deviation for continuous variables. Effect size was assessed using partial eta squared test where values of 0.01, 0.06, and 0.14 signify small, medium, and large effect size, respectively. Repeated measures analysis of variance test was used for comparison of means and assessment of QOL between the EORTC and RTOG groups at 6 months. Absolute volume of planning target volume (PTV) receiving 46 and 60 Gy were described, PTV 46/60 was also described in terms of % of whole brain volume.

Results Eighteen patients underwent randomization (9 in EORTC and RTOG group each). Statistically significant improvement was noted in the overall posttreatment values in the physical well-being (PWB) domain (p = 0.007).

Conclusion This is the first study to compare the EORTC and RTOG delineation techniques in terms of QOL. No significant differences in QOL were noted between the two arms. Significant improvement was noted posttreatment in PWB of overall patients.

Keywords

glioma - high-grade - brain - radiotherapy - quality of life - neurocognitive functions - FACT-Br

Authors' Contributions

All participants contributed equally to this study.




Publication History

Article published online:
21 April 2025

© 2025. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 31-Brain-central-nervous-system-fact-sheet.pdf. Accessed April 2, 2025 at: https://gco.iarc.fr/today/data/factsheets/cancers/31-Brain-central-nervous-system-fact-sheet.pdf
  • 2 Dong X, Noorbakhsh A, Hirshman BR. et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neurooncol Pract 2016; 3 (01) 29-38
    PubMedSearch in Google Scholar
  • 3 Shin DW, Lee S, Song SW. et al. Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases. Sci Rep 2020; 10 (01) 20162
    PubMedSearch in Google Scholar
  • 4 Kristiansen K, Hagen S, Kollevold T. et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981; 47 (04) 649-652
    PubMedSearch in Google Scholar
  • 5 Niyazi M, Brada M, Chalmers AJ. et al ESTRO-ACROP guideline “target delineation of glioblastomas.”. Radiother Oncol 2016; 118 (01) 35-42
    PubMedSearch in Google Scholar
  • 6 Walker MD, Alexander E, Hunt WE. et al Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 1978; 49 (03) 333-343
    CrossrefPubMedSearch in Google Scholar
  • 7 Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med 2015; 3 (07) 95
    PubMedSearch in Google Scholar
  • 8 Hu LS, Eschbacher JM, Dueck AC. et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 2012; 33 (01) 69-76
    PubMedSearch in Google Scholar
  • 9 Taw BB, Gorgulho AA, Selch MT, De Salles AA. Radiation options for high-grade gliomas. Neurosurg Clin N Am 2012; 23 (02) 259-267 , viii
    PubMedSearch in Google Scholar
  • 10 Liu S, Zhao Q, Shi W. et al. Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. J Cancer 2021; 12 (04) 1094-1104
    PubMedSearch in Google Scholar
  • 11 Ten Haken RK, Thornton Jr AF, Sandler HM. et al. A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors. Radiother Oncol 1992; 25 (02) 121-133
    PubMedSearch in Google Scholar
  • 12 Stupp R, Mason WP, van den Bent MJ. et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
    CrossrefPubMedSearch in Google Scholar
  • 13 Burger PC, Dubois PJ, Schold Jr SC. et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983; 58 (02) 159-169
    PubMedSearch in Google Scholar
  • 14 Halperin EC, Bentel G, Heinz ER, Burger PC. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 1989; 17 (06) 1347-1350
    PubMedSearch in Google Scholar
  • 15 Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16 (06) 1405-1409
    PubMedSearch in Google Scholar
  • 16 Liang BC, Thornton Jr AF, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991; 75 (04) 559-563
    CrossrefPubMedSearch in Google Scholar
  • 17 Chang EL, Akyurek S, Avalos T. et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007; 68 (01) 144-150
    PubMedSearch in Google Scholar
  • 18 Minniti G, Amelio D, Amichetti M. et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010; 97 (03) 377-381
    PubMedSearch in Google Scholar
  • 19 Gilbert MR, Dignam JJ, Armstrong TS. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (08) 699-708
    CrossrefPubMedSearch in Google Scholar
  • 20 Guram K, Smith M, Ginader T. et al. Using smaller-than-standard radiation treatment margins does not change survival outcomes in patients with high-grade gliomas. Pract Radiat Oncol 2019; 9 (01) 16-23
    PubMedSearch in Google Scholar
  • 21 Paulsson AK, McMullen KP, Peiffer AM. et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol 2014; 37 (02) 177-181
    PubMedSearch in Google Scholar
  • 22 Marks LB, Yorke ED, Jackson A. et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76 (3, Suppl): S10-S19
    CrossrefPubMedSearch in Google Scholar
  • 23 Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30 (09) 907-911
    PubMedSearch in Google Scholar
  • 24 Cheng JX, Zhang X, Liu BL. Health-related quality of life in patients with high-grade glioma. Neuro-oncol 2009; 11 (01) 41-50
    PubMedSearch in Google Scholar
  • 25 Gilbert MR, Wang M, Aldape KD. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013; 31 (32) 4085-4091
    PubMedSearch in Google Scholar
  • 26 Cella D, Chang CH, Lai JS, Webster K. Advances in quality of life measurements in oncology patients. Semin Oncol 2002; 29 (3, Suppl 8): 60-68
    PubMedSearch in Google Scholar
  • 27 Klein E, Altshuler D, Hallock A, Szerlip N. Quality of life research in neuro-oncology: a quantitative comparison. J Neurooncol 2014; 116 (02) 333-340
    PubMedSearch in Google Scholar
  • 28 Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Levin VA, Cella DF. The Functional Assessment of Cancer Therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995; 75 (05) 1151-1161
    CrossrefPubMedSearch in Google Scholar
  • 29 Dirven L, Aaronson NK, Heimans JJ, Taphoorn MJ. Health-related quality of life in high-grade glioma patients. Chin J Cancer 2014; 33 (01) 40-45
    PubMedSearch in Google Scholar
  • 30 Park DY, Tom MC, Wei W. et al. Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma. J Neurooncol 2022; 156 (03) 499-507
    PubMedSearch in Google Scholar
  • 31 Drewes C, Sagberg LM, Jakola AS, Solheim O. Perioperative and postoperative quality of life in patients with glioma–a longitudinal cohort study. World Neurosurg 2018; 117: e465-e474
    PubMedSearch in Google Scholar
  • 32 Kumar N, Kumar R, Sharma SC. et al. Impact of volume of irradiation on survival and quality of life in glioblastoma: a prospective, phase 2, randomized comparison of RTOG and MDACC protocols. Neurooncol Pract 2020; 7 (01) 86-93
    PubMedSearch in Google Scholar
  • 33 Yan O, Teng H, Jiang C. et al. Comparative dosimetric study of radiotherapy in high-grade gliomas based on the guidelines of EORTC and NRG-2019 target delineation. Front Oncol 2023; 13: 1108587
    PubMedSearch in Google Scholar
  • 34 Haraldseide LM, Jakola AS, Solheim O, Sagberg LM. Does preoperative health-related quality of life predict survival in high-grade glioma patients? - a prospective study. Br J Neurosurg 2020; 34 (01) 28-34
    PubMedSearch in Google Scholar
  • 35 Bitterlich C, Vordermark D. Analysis of health-related quality of life in patients with brain tumors prior and subsequent to radiotherapy. Oncol Lett 2017; 14 (02) 1841-1846
    PubMedSearch in Google Scholar